Article

New Partnership Established: Alfa Chemistry Adds 200,000+ Chemicals to Spaya Database

Topic: Business DevelopmentPublished May 17, 2023

Legacy signals

Legacy popularity: 230 legacy views

In a recent statement, the US-based chemical supplier Alfa Chemistry announced that it has added more than 200,000 chemicals to Spaya's chemical structure collection database. The partnership between Alfa Chemistry and Spaya, a platform that uses a data-driven AI approach to discover retrosynthetic routes, will provide customers with unparalleled access to a wide range of Alfa Chemistry's extensive network of chemicals. Following this move, Alfa Chemistry's existing and new customers will have more diversified options and solutions when selecting the most appropriate chemicals for their R&D projects. "Over the past decade, we have made tremendous efforts to expand our reach and make our products more accessible to customers," said Alfa Chemistry's marketing director. "We believe that this partnership will bring win-win results. For us, the majority of our chemical structures and substances are now searchable in the Spaya database. For Spaya, its platform is now more powerful with an expanded collection to better serve its community of online chemists, researchers and scientists by offering more options.” Alfa Chemistry has listed a comprehensive range of chemicals in the Spaya Database, which can be widely used in various applications such as pharmaceutical, life science, biotechnology and academic industries. Some of the featured offerings are listed below: Active Pharmaceutical Ingredients (APIs)rnThe quality of an API plays a very important role in drugs. API can be in the form of liquids, powders, crystals obtained by chemical synthesis, biotechnology or plant extraction. After continuous improvement, Alfa Chemistry now offers the following APIs Acetazolamide, Ancitabine Hydrochloride, Benzhexol Hydrochloride, Chlorquinaldol, Cyclophosphamide, Cytarabine Hydrochloride, Fluorouracil, Glycine, Hydrocortisone Butyrate, Ifosfamide, Ilepcimide, Letrozole, Levodopa, Memantine Hydrochloride, Methotrexate, Metoprolol Tartrate, Nifedipine, Nimustine Hydrochloride, Oseltamivir Phosphate, Promestriene, Protamine Sulfate, Sulfamethoxazole, Zinc Gluconate, Donepezil, Edaravone, Lenalidomide, Parecoxib Sodium, Rivaroxaban, Tofacitinib Citrate, Tamoxifen Citrate, Epalrestat, Dexmedetomidine Hydrochloride, Moxifloxacin Hydrochloride, MRTX0902, and PF-06821497. COVID-19 Drug Raw MaterialsrnAlfa Chemistry has been a professional supplier of COVID-19 drug raw materials, such as: 28-Oxo Ivermectin B1a (Impurity) (CAS 102190-55-6 ), 5-O-Demethyl-28-oxo-Avermectin A1a (CAS 102190-68-1), Dexamethasone-17-acetate (CAS 1177-87-3), Baricitinib (CAS 1187594-09-7), Ciclesonide (CAS 126544-47-6), Chebulic acid (CAS 23725-05-5), N(4)-hydroxycytidine (CAS 3258-02-4), etc. Peptide (extracted)rnIn recent years, peptides have received increasing interest in pharmaceutical, food, cosmetic and various other fields. Alfa Chemistry's wide range of high quality extracted peptides includes: hydrolyzed protein peptides, fish collagen peptides, marine fish oligopeptides, oyster peptides, sea cucumber peptides, pea peptides, soybean peptides, and walnut peptides. NanomaterialsrnNanomaterials are up to 10,000 times smaller than the width of a human hair. And this tiny size makes them very valuable for all kinds of practical applications. Alfa Chemistry has developed almost every type of nanomaterial, including Mxene materials, nanofoils, nanoprisms, nanorods, nanospheres, nanotubes, nanowires, porous nanomaterials, quantum dots, targets/wafers, nanofibers, nanoparticles and nanocarbon. In addition, many other novel materials such as battery materials, chips/pellets/metal balls, ITO-coated glass, metal foams, metal foils, metal-organic frameworks, metal wires, nanofabric coatings, nano rare earth materials, polymer nanomaterials, screen-printed electrodes, and semiconductor materials are also readily available at Alfa Chemistry. "All in all, this newly formed partnership between Alfa Chemistry and Spaya Database is a momentous event that aims to revolutionize the scope of the chemical industry and simplify scientific research. Through this partnership, customers now have a comprehensive database that provides an all-in-one solution to meet all their chemical needs," added the Marketing Director.

Further reading

Further Reading

4 total

Article

Artificial intelligence continues to dominate business conversations, but enthusiasm alone does not guarantee results. While many companies rush to adopt AI in hopes of gaining a competitive edge, a large number of initiatives still fall short. The problem is rarely the technology itself. More often, failure happens because organizations approach AI without the structure, readiness, and discipline required for long-term success. AI projects do not fail because the technology

March 4, 2026

Article

AI Avatar Development: Real Innovation or Just Hype? In today’s hyperconnected world, attention is currency. To stand out, brands can no longer settle for flashy features or surface-level engagement. They need to build meaningful, scalable, and personalized experiences. Enter AI avatars: digital humans that are revolutionizing communication by bringing lifelike presence to virtual interactions. Imagine a team member who never takes a coffee break, speaks ten languages fluen

February 27, 2026

Article

The Quiet Engine Behind Every Connection Most people think of telecom services as towers, signals, and mobile data moving invisibly through the air. Yet behind every call that connects and every message that reaches its destination, there is another system quietly working in the background. That system is the call center. While customers often interact with telecom companies only when something goes wrong, these centers operate constantly, guiding problems toward solutions an

February 23, 2026

Article

Introduction The solar industry once believed that collecting as many leads as possible was the fastest path to growth. Marketing teams focused on filling databases with names, phone numbers, and email addresses. At first, the numbers looked promising. Dashboards showed rising interest and more inquiries than ever before. Yet behind the scenes, many companies began to notice a quiet problem. Revenue growth did not match the flood of leads. Sales teams felt overwhelmed, conver

February 6, 2026